Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for BioCorRx (BICX) over the last 13 years, with Q3 2025 value amounting to $16060.0.

  • BioCorRx's Share-based Compensation fell 4511.47% to $16060.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $483565.0, marking a year-over-year increase of 6332.3%. This contributed to the annual value of $1.2 million for FY2024, which is 34007.65% up from last year.
  • Latest data reveals that BioCorRx reported Share-based Compensation of $16060.0 as of Q3 2025, which was down 4511.47% from $30715.0 recorded in Q2 2025.
  • Over the past 5 years, BioCorRx's Share-based Compensation peaked at $285533.0 during Q4 2024, and registered a low of $3686.0 during Q2 2021.
  • In the last 5 years, BioCorRx's Share-based Compensation had a median value of $34489.0 in 2023 and averaged $69937.2.
  • In the last 5 years, BioCorRx's Share-based Compensation plummeted by 5994.78% in 2021 and then skyrocketed by 64623.79% in 2024.
  • Quarter analysis of 5 years shows BioCorRx's Share-based Compensation stood at $43175.0 in 2021, then surged by 64.45% to $71001.0 in 2022, then crashed by 46.11% to $38263.0 in 2023, then skyrocketed by 646.24% to $285533.0 in 2024, then tumbled by 94.38% to $16060.0 in 2025.
  • Its last three reported values are $16060.0 in Q3 2025, $30715.0 for Q2 2025, and $151257.0 during Q1 2025.